SEHK:3320Pharmaceuticals
China Resources Pharmaceutical Group SEHK 3320 Earnings Growth Reinforces Bullish Narrative Despite Thin Margins
China Resources Pharmaceutical Group (SEHK:3320) FY 2025 Earnings Snapshot
China Resources Pharmaceutical Group (SEHK:3320) has posted its latest FY 2025 numbers with first half revenue of about C¥131.9b and basic EPS of C¥0.33, set against trailing twelve month EPS of C¥0.64. The company has seen revenue move from roughly C¥128.6b in 1H 2024 to C¥131.9b in 1H 2025, while basic EPS shifted from C¥0.41 in 1H 2024 and C¥0.12 in 2H 2024 to C¥0.33 in the latest half. This sets up a discussion...